Skip to main content
. 2017 Aug 30;7:9973. doi: 10.1038/s41598-017-10556-y

Table 2.

Risk of the Atrial Fibrillation and Thromboembolic Events in Psoriasis Patients by the Severity.

Outcomes No. of events Incidence* Unadjusted Multivariable adjusted PS-matched
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Atrial Fibrillation
  Non-psoriasis 12143/739459 1.65 1.00 (reference) 1.00 (reference) 1.00 (reference)
  Mild psoriasis 257/11438 2.48 1.51 (1.34–1.71) <0.001 1.10 (0.97–1.24) 0.133 1.06 (0.93–1.22) 0.365
  Severe psoriasis 72/1947 4.05 2.47 (1.96–3.11) <0.001 1.44 (1.14–1.82) 0.002 1.77 (1.39–2.24) <0.001
Thromboembolic Events
  Non-psoriasis 26406/739459 3.63 1.00 (reference) 1.00 (reference) 1.00 (reference)
  Mild psoriasis 571/11438 5.13 1.41 (1.30–1.54) <0.001 1.04 (0.96–1.13) 0.382 0.98 (0.90–1.08) 0.707
  Severe psoriasis 152/1947 8.14 2.25 (1.91–2.63) <0.001 1.26 (1.07–1.47) 0.005 1.55 (1.32–1.84) <0.001

*Incidence rates were calculated per 1000 patient-years, within the population who were over 20 years old and not previously diagnosed with atrial fibrillation.

Multivariable adjusted hazard ratios were calculated by Cox regression models, including age over 65, gender, income level, resident area, hypertension, diabetes, dyslipidemia, congestive heart failure, peripheral arterial disease, prior history of stroke, prior history of myocardial infarction, use of platelet inhibitors, and use of vitamin K antagonists as covariates.

Severe psoriasis patients included those with psoriatic arthritis, and those receiving systemic anti-psoriatic treatment, as previously established and validated.

Abbreviations: CI, confidence interval; HR, hazard ratio; PS, propensity score.